Dutch vaccine developer Mucosis has announced that John Lambert has been elected as the new chairman of its supervisory board. Mucosis is developing vaccines based on particles created from inactivated Lactococcus lactis bacteria, including its lead candidate, an intranasal influenza vaccine called FluGEM. Read the company’s press release
